Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma

NCT00005855 is registered in ClinicalTrials.gov with New Approaches to Brain Tumor Therapy Consortium as lead sponsor.

NCT NCT00005855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2000
Completion date
October 31, 2006
Enrollment
48 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors